Sulfonamides as Inhibitors of Leishmania – Potential New Treatments for Leishmaniasis
نویسندگان
چکیده
Introduction Leishmaniasis is an endemic disease caused by the protozoan parasite Leishmania. Current treatments for the parasite are limited by cost, availability and drug resistance as the occurrence of leishmaniasis continues to be more prevalent. Sulfonamides are a class of compounds with medicinal properties which have been used to treat bacterial and parasitic disease via various pathways especially as antimetabolites for folic acid. Methods New derivatives of sulfonamide compounds were assessed for their impact on Leishmania cell viability and potential pathways for inhibition were evaluated. Leishmania tarentolae (ATCC Strain 30143) axenic promastigote cells were grown in brain heart infusion (BHI) medium and treated with varying concentrations of the new sulfonamide compounds. Light microscopy and viability tests were used to assess the cells with and without treatment. Discussion A non-water soluble sulfonamide was determined to have 90-96% viability inhibition 24 hours after treatment with 100 µM final concentration. Because Leishmania are also autotrophs for folate precursors, the folic acid pathway was identified as a target for sulfonamide inhibition. When folic acid was added to untreated Leishmania, cell proliferation increased. A water soluble derivative of the inhibitory sulfonamide was synthesized and evaluated, resulting in less viability inhibition with a single dose (approximately 70% viability inhibition after 24 hours with 100 µM final concentration), but additive inhibition with multiple doses of the compound. Results However, the potential mechanism of inhibition was different between the water-soluble and non-water soluble sulfonamides. The inhibitory effects and potential pathways of inhibition indicate that these compounds may be new treatments for this disease.
منابع مشابه
In Silico Search of Energy Metabolism Inhibitors for Alternative Leishmaniasis Treatments
Leishmaniasis is a complex disease that affects mammals and is caused by approximately 20 distinct protozoa from the genus Leishmania. Leishmaniasis is an endemic disease that exerts a large socioeconomic impact on poor and developing countries. The current treatment for leishmaniasis is complex, expensive, and poorly efficacious. Thus, there is an urgent need to develop more selective, less ex...
متن کاملCharacterization of Acid Phosphatase in the Promastigotes of Three Isolates of Leishmania major
Background: Acid phosphatase (ACP) is suggested to be one of the virulence factors in leishmania and a correlation has been reported between Leishmanial acid phosphatase (ACP) activity and the severity of the disease in all types of leishmaniasis including zoonotic cutaneous leishmaniasis (ZCL), which is a polymorphic disease. Objective: Characterization of leishmania and its correlation with t...
متن کاملActivity of anti-cancer protein kinase inhibitors against Leishmania spp.
OBJECTIVES There is an urgent need to develop new and effective treatments for poverty-related neglected diseases. In light of the time required to bring a new drug to market and the cost involved (10-15 years, >1 billion US$), one approach to identifying new treatments for diseases like leishmaniasis is to evaluate drugs that are already registered for the treatment of other diseases. This pap...
متن کاملCloning and Expression of Leishmania major Superoxide Dismutase B1: A Potential Target Antigen for Serodiagnosis of Leishmaniasis
متن کامل
Protease inhibitors in potential drug development for Leishmaniasis.
Leishmaniasis is a deadly protozoan parasitic disease affecting millions of people worldwide. The treatment strategy of Leishmania infection depends exclusively on chemotherapy till date. But the treatment of the disease is greatly hampered due to high cost, toxicity of the available drugs and more importantly emergence of drug resistance. Hence the potential new drugs are highly needed to comb...
متن کامل